Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADAMTS7 | Q9UKP4 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899962 | 0.86 | ADAMTS4 (0.46) | ADAMTS5ADAMTS4MMP2MMP3MMP12 | |
| SCHEMBL999490 | 0.72 | CTSD (0.61) | ALDH1A1MAPTHPGDCYP3A4TSHR | |
| SCHEMBL3247075 | 0.71 | ADAMTS5 (0.48) | ADAMTS5ADAMTS4MMP2MMP3MMP12 | |
| SCHEMBL28395903 | 0.70 | TSHR (0.62) | ALDH1A1MAPTCYP3A4TSHRSLC6A2 | |
| SCHEMBL12609468 | 0.70 | LMNA (0.53) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL23354303 | 0.69 | ADAMTS5 (0.51) | ADAMTS5ADAMTS4MMP2MMP3MMP12 | |
| SCHEMBL4304944 | 0.68 | TSHR (0.58) | ALDH1A1MAPTHPGDCYP3A4TSHR | |
| SCHEMBL29935450 | 0.66 | DTYMK (0.62) | ALDH1A1MAPTCYP3A4TSHRL3MBTL1 | |
| SCHEMBL149316 | 0.66 | DTYMK (0.62) | ALDH1A1MAPTCYP3A4TSHRL3MBTL1 | |
| SCHEMBL1277039 | 0.66 | TSHR (0.60) | ALDH1A1MAPTHPGDCYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879890-B2 | hydantoin derivatives that can inhibit matrix metalloproteinases and tumor necrosis factor alpha-converting enzyme, to prevent the release of tumor necrosis factor; treatment of septic shock, reperfusion injuries, meningitis, psoriasis, arthritis, inflammatory bowel disease and ankylosing spondylitis | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7687527-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7683085-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-04-30 | — | — | US | disclosed |
| US-7504424-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7488745-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7482370-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-09-20 | — | — | US | disclosed |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111803-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | ADAMTS5 13/4885ADAMTS4 19/4885MMP2 33/4885 |
| US-20070219218-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | ADAMTS5 4/4885ADAMTS4 7/4885MMP2 30/4885 |
| US-20090170875-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | ADAMTS5 4/4885ADAMTS4 7/4885MMP2 30/4885 |
| US-20090137586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | ADAMTS5 4/4885ADAMTS4 7/4885MMP2 30/4885 |
| US-20060276506-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | ADAMTS5 4/4885ADAMTS4 7/4885MMP2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.